Introgen Therapeutics, Inc.

(NASDAQ:INGN)
  Sep 30, 2008 Jun 30, 2008 Mar 31, 2008 Dec 31, 2007
Operating revenue
Total Revenue 331 121 186 468
Operating Revenue 331 121 186 468
Adjustments To Revenue — — — —
Cost Of Sales -251 -248 -247 -230
Cost Of Sales With Depreciation — — — —
Gross Operating Profit 582 369 433 698
Operating Expenses
Research And Development Expenses 3,784 4,154 4,682 6,090
Selling General And Administrative Expenses 2,699 2,490 2,531 4,175
Advertising Expenses — — — —
Operating Income Before Depreciation -5,901 -6,275 -6,780 -9,567
Operating Income -6,152 -6,523 -7,027 -9,797
Depreciation 251 248 247 230
Depreciation Unreconciled — — — —
Amortization — — — —
Amortization Of Intangibles — — — —
Operating Income After Depreciation -6,152 -6,523 -7,027 -9,797
Non Operating Expenses
Interest Expense 155 163 162 167
Pre Tax Income -5,975 -6,346 -2,405 -9,537
Income Taxes — — — —
Minority Interest — — -4 6
Income Before Income Taxes — — — —
Net Income From Continuing Operations -5,975 -6,346 -2,401 -9,543
Net Income From Discontinued Operations — — — —
Net Income From Total Operations -5,975 -6,346 -2,401 -9,543
Non Recurring Events
Extraordinary Income Losses — — — —
Income From Cummulated Effect Of Accounting Changes — — — —
Income From Tax Loss Carryforward — — — —
Other Gains And Losses — — — —
Total Net Income -5,975 -6,346 -2,401 -9,543
Normalized Income -5,975 -6,346 -2,401 -9,543
NetIncome Available For Common -5,975 -6,346 -2,401 -9,543
Preferred Dividends — — — —
Excise Taxes — — — —